Transgenic Animal Welfare in Research

The creation and use of genetically modified animals in research raises distinctive welfare considerations beyond those of standard laboratory animal use, including unpredictable phenotype expression and welfare screening challenges.

Key Facts

Over 1 million genetically modified mice are used in UK research annually, a majority of all mice used
Genetic modifications sometimes produce unexpected welfare-compromising phenotypes not intended by researchers
Mandatory welfare screening of new transgenic lines is required in many jurisdictions but implementation varies
Homozygous transgenic animals may express more severe phenotypes than heterozygous controls
Some transgenic models develop conditions causing chronic pain, immunodeficiency, or early death
The Three Rs framework requires assessment of whether transgenic models can be replaced by alternatives
Humane endpoints for transgenic lines must be specifically defined based on expected phenotype progression

Welfare Considerations

Transgenic animals occupy a unique welfare category because their suffering may result from the research intervention itself rather than experimental procedures. A transgenic mouse model of neurodegeneration, for example, is engineered to experience progressive disability — welfare harms are built into the model by design. This demands particularly rigorous application of the Three Rs, including genuine consideration of non-animal alternatives, minimizing the severity of transgenic phenotypes through model design choices, and establishing clear welfare monitoring criteria before lines are established. Researchers should track and report welfare outcomes for transgenic lines as a standard publication requirement.

What You Can Do

Support mandatory welfare screening protocols for all new transgenic animal lines
Advocate for publication requirements including welfare data from transgenic studies
Encourage researchers to consider whether humanized cell or organoid models can replace transgenic animals
Promote humane endpoint training specific to common transgenic model phenotypes
Back funding for developing validated non-animal models of human genetic diseases